Dumirox and Actemra, which are monopolized by JW Pharma's domestic development and copyright, are emerging as a possible treatment for COVID-19

On the 8th, the MFDS approved sponsor-investigator trials for patients with COVID-19 of Dumirox 100mg (Fluvoxamine maleate), an antidepressant drug.

With the approval of this clinical plan, AMC will conduct a randomized, placebo-controlled method to investigate the treatment effect of Fluvoxamine maleate for 406 mild COVID-19 patients admitted to the Community Treatment Centers.

Dumirox is a selective serotonin reuptake inhibitor as an antidepressant primarily prescribed for patients with depression and obsessive-compulsive disorder